Yihong Yao

Home / About Us / Management / Yihong Yao

yao_yihongChief Scientific Officer

Yihong Yao, PhD, BS

  • Former MedImmune/AstraZeneca Director
  • B.S. degree Biochemistry, Department of Biochemistry, Fu Dan University, Shanghai, China
  • Master’s Degree bioinformatics, Boston University
  • Ph.D. Molecular Biology & Biochemistry, Department of Biochemistry, University of Kansas,
  • Postdoctoral Fellowship, Johns Hopkins University, School of Medicine, Baltimore, Maryland

Dr. Yao has nearly twenty years of experience in the life sciences industry and academia with strong expertise in clinical biomarker discovery and development, strategy and personalized medicine.

Dr. Yao received his B.S. degree in Biochemistry from the Department of Biochemistry, Fu Dan University, Shanghai, China, a Master’s Degree in bioinformatics from Boston University and his Ph.D. in Molecular Biology & Biochemistry from the Department of Biochemistry, University of Kansas, Lawrence, Kansas, USA. He completed his Postdoctoral Fellowship at Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA. In addition to his strong academic background, he has over fifteen years of professional experience with pharmaceutical and biotechnology companies including MedImmune biologics research and development arm of AstraZeneca, and Abbott Bioresearch Center.

Dr. Yao is the co-inventor of twenty-six filed patents relating to tumor classification, degenerative muscle disease and autoimmune disease diagnostics and treatment. He has published over sixty papers in translational science peer-reviewed journals and has authored or co-authored two books on the subjects of inflammatory and autoimmune diseases and genomic biomarkers.

Dr. Yao is a frequently invited speaker and panelist for many international conferences on biomarkers, personalized medicine, miRNA, rheumatology and oncology.

Dr. Yao spearheads the Company’s overall scientific research programs in the areas of Immuno-Oncology and inflammatory/autoimmune diseases and is responsible for strengthening the Company’s Immuno-Oncology platforms and clinical trial design and bioinformatics.